JP6898240B2 - T細胞前駆細胞を生成するための方法 - Google Patents

T細胞前駆細胞を生成するための方法 Download PDF

Info

Publication number
JP6898240B2
JP6898240B2 JP2017537016A JP2017537016A JP6898240B2 JP 6898240 B2 JP6898240 B2 JP 6898240B2 JP 2017537016 A JP2017537016 A JP 2017537016A JP 2017537016 A JP2017537016 A JP 2017537016A JP 6898240 B2 JP6898240 B2 JP 6898240B2
Authority
JP
Japan
Prior art keywords
cells
medium
progenitor cells
cell
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017537016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531448A (ja
JP2017531448A5 (https=
Inventor
マリーナ カヴァッツァーナ
マリーナ カヴァッツァーナ
イザベル アンドレ−シュムッツ
イザベル アンドレ−シュムッツ
シャンタル ラグレル−ペイルー
シャンタル ラグレル−ペイルー
サリマ ハサイン−ベイ−アビナ
サリマ ハサイン−ベイ−アビナ
クリスティアン ライマン
クリスティアン ライマン
シャプドレーヌ コリーヌ ド
シャプドレーヌ コリーヌ ド
エマニエル シックス
エマニエル シックス
Original Assignee
アシスタンス パブリック−ホピトー デ パリ
アシスタンス パブリック−ホピトー デ パリ
フォンダシオン イマジネ アンスティチュ デ マラディース ジェネティクス
フォンダシオン イマジネ アンスティチュ デ マラディース ジェネティクス
ユニベルシテ パリ デカルト
ユニベルシテ パリ デカルト
インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル (インセルム)
インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル (インセルム)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アシスタンス パブリック−ホピトー デ パリ, アシスタンス パブリック−ホピトー デ パリ, フォンダシオン イマジネ アンスティチュ デ マラディース ジェネティクス, フォンダシオン イマジネ アンスティチュ デ マラディース ジェネティクス, ユニベルシテ パリ デカルト, ユニベルシテ パリ デカルト, インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル (インセルム), インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル (インセルム) filed Critical アシスタンス パブリック−ホピトー デ パリ
Publication of JP2017531448A publication Critical patent/JP2017531448A/ja
Publication of JP2017531448A5 publication Critical patent/JP2017531448A5/ja
Application granted granted Critical
Publication of JP6898240B2 publication Critical patent/JP6898240B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/42Notch; Delta; Jagged; Serrate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114T cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/50Proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/50Proteins
    • C12N2533/52Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
JP2017537016A 2014-10-06 2015-10-05 T細胞前駆細胞を生成するための方法 Active JP6898240B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1459539 2014-10-06
FR1459539A FR3026744B1 (fr) 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t
PCT/EP2015/072889 WO2016055396A1 (fr) 2014-10-06 2015-10-05 Méthode de génération de progéniteurs de cellules t

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020209370A Division JP2021072779A (ja) 2014-10-06 2020-12-17 T細胞前駆細胞を生成するための方法

Publications (3)

Publication Number Publication Date
JP2017531448A JP2017531448A (ja) 2017-10-26
JP2017531448A5 JP2017531448A5 (https=) 2018-11-15
JP6898240B2 true JP6898240B2 (ja) 2021-07-07

Family

ID=52102849

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017537016A Active JP6898240B2 (ja) 2014-10-06 2015-10-05 T細胞前駆細胞を生成するための方法
JP2020209370A Pending JP2021072779A (ja) 2014-10-06 2020-12-17 T細胞前駆細胞を生成するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020209370A Pending JP2021072779A (ja) 2014-10-06 2020-12-17 T細胞前駆細胞を生成するための方法

Country Status (11)

Country Link
US (1) US12071635B2 (https=)
EP (2) EP3204492B1 (https=)
JP (2) JP6898240B2 (https=)
CA (1) CA2963756C (https=)
DK (1) DK3204492T3 (https=)
ES (1) ES2914082T3 (https=)
FR (1) FR3026744B1 (https=)
HU (1) HUE059468T2 (https=)
PL (1) PL3204492T3 (https=)
PT (1) PT3204492T (https=)
WO (1) WO2016055396A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173551A1 (en) 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
AU2019252878B2 (en) * 2018-04-10 2024-02-22 Stichting Sanquin Bloedvoorziening Chimeric Notch receptors
JP2023553313A (ja) 2020-11-30 2023-12-21 チョ ファーマ インコーポレイテッド 細胞を富化するための抗体
WO2023079082A1 (en) 2021-11-04 2023-05-11 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
KR20250152088A (ko) 2023-02-22 2025-10-22 메이라지티엑스 셀 테라피스 흉선 재생 방법
KR20260041821A (ko) 2023-07-12 2026-03-27 메이라지티엑스 셀 테라피스 특이적 동형접합성 hla 일배체형을 갖는 세포 뱅크의 바이오뱅크 및 환자 치료를 위한 이의 용도
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
WO2025255678A1 (en) * 2024-06-14 2025-12-18 Stemcell Technologies Canada Inc. Compositions and methods for generating lymphoid lineage cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO1999028486A1 (en) 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
KR101331746B1 (ko) * 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
EP2331679B1 (en) 2008-09-12 2017-04-19 Cryopraxis Criobiologia LTDA. Ischemic tissue cell therapy
AU2009311232B2 (en) 2008-11-07 2014-10-30 Sunnybrook Health Sciences Centre Human progenitor T-cells
US8871510B2 (en) * 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
CA2795627C (en) 2010-04-09 2023-03-14 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
EP2788476B1 (en) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2014110353A1 (en) * 2013-01-11 2014-07-17 The Trustees Of The University Of Pennsylvania Notch ligand bound bicompatible substrates and their use in bone formation
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
CA2945388A1 (en) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
CN106062185A (zh) 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
WO2016039933A1 (en) * 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders

Also Published As

Publication number Publication date
US20180208895A1 (en) 2018-07-26
EP3204492A1 (fr) 2017-08-16
PL3204492T3 (pl) 2022-07-25
JP2021072779A (ja) 2021-05-13
EP4036224A1 (fr) 2022-08-03
FR3026744A1 (fr) 2016-04-08
ES2914082T8 (es) 2022-06-16
FR3026744B1 (fr) 2024-04-19
PT3204492T (pt) 2022-05-30
DK3204492T3 (da) 2022-06-07
US12071635B2 (en) 2024-08-27
WO2016055396A1 (fr) 2016-04-14
CA2963756A1 (fr) 2016-04-14
JP2017531448A (ja) 2017-10-26
ES2914082T3 (es) 2022-06-07
HUE059468T2 (hu) 2022-12-28
CA2963756C (fr) 2024-01-02
EP3204492B1 (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
JP6898240B2 (ja) T細胞前駆細胞を生成するための方法
US11642376B2 (en) Method for generating T cell progenitors
KR20180057641A (ko) 자연살해 세포의 증식방법
KR20110006705A (ko) 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
US20130142766A1 (en) Production method for cell populations
EP4600352A1 (en) T cell production method
JP5485139B2 (ja) 遺伝子導入細胞の製造方法
HK40081656A (en) Method for generating t cells progenitors
WO2022210399A1 (ja) 遺伝子改変細胞およびその製造方法
WO2025094915A1 (ja) 細胞傷害性t細胞の製造方法
HK40017982B (en) Method for generating t cells progenitors
HK40017982A (en) Method for generating t cells progenitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201217

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210402

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210610

R150 Certificate of patent or registration of utility model

Ref document number: 6898240

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250